Does Blue Cross Blue Shield of Massachusetts Cover Trulicity?

What Is Trulicity and Why Does Formulary Placement Matter?

Trulicity (dulaglutide) is a once-weekly injectable GLP-1 receptor agonist approved by the FDA in 2014 for glycemic control in adults with type 2 diabetes. The FDA also approved a cardiovascular indication, making it one of the few GLP-1 agents with label language for reducing major adverse cardiovascular events in patients with established cardiovascular disease or multiple risk factors. Trulicity FDA label [1]

Formulary placement determines what you pay. Most large commercial insurers organize drugs into tiers. A Tier 1 generic costs a few dollars per fill. A Tier 3 or Tier 4 brand-name drug like Trulicity can cost hundreds of dollars monthly even after insurance applies its discount. Because BCBS MA operates multiple plan types, including HMO Blue, Blue Choice, and PPO products sold through employers and MassHealth-adjacent plans, Trulicity's tier and your co-pay are not identical across every member.

How Formulary Tiers Work in Practice

A formulary is the insurance plan's approved drug list. Each drug sits in a tier, and the tier dictates the co-pay or coinsurance rate. The FDA drug approval database [2] confirms dulaglutide's original 2014 approval, which set the clock for Eli Lilly's market exclusivity period. Because no generic dulaglutide is currently available in the United States, every BCBS MA member fills the brand-name product and pays at the branded tier rate.

Why the Cardiovascular Indication Changes the Coverage Calculus

The REWIND trial (N=9,901, median follow-up 5.4 years) demonstrated that dulaglutide 1.5 mg once weekly reduced the composite endpoint of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death by 12% relative to placebo (HR 0.88; 95% CI 0.79 to 0.99; P<0.026) in patients with type 2 diabetes. REWIND trial, The Lancet [3] That cardiovascular outcomes data sometimes supports prior authorization approvals when a patient has documented atherosclerotic cardiovascular disease, because the insurer's medical policy may separately acknowledge the CV indication.

Does BCBS MA Specifically Cover Trulicity?

Yes, BCBS MA covers Trulicity on most commercial formularies, but the plan type, employer benefit design, and individual clinical history all affect whether a member receives coverage without additional hurdles. The drug appears on the BCBS MA commercial formulary for type 2 diabetes, generally at Tier 3, meaning it is a preferred brand in some plans or a non-preferred brand in others.

Commercial Plans vs. Medicare Advantage vs. Medicaid

BCBS MA administers several distinct plan types, and Trulicity's coverage status differs across them.

Commercial employer plans: Most employer-sponsored BCBS MA plans list Trulicity at Tier 3 or Tier 4 with prior authorization required. Co-pays commonly fall between $75 and $200 per 30-day supply at Tier 3, though high-deductible health plans may require members to meet the deductible first.

Medicare Advantage (Blue Medicare HMO/PPO): Medicare Part D plans operate under a separate formulary. The CMS Medicare Part D formulary requirements [4] mandate that plans cover at least two drugs in each therapeutic category. Dulaglutide appears on many Medicare Part D formularies, including some BCBS MA Medicare Advantage plans, but the tier and cost-sharing differ materially from commercial plans. Some members pay $47, $100 at Tier 3 under Medicare; others face higher costs.

MassHealth (Medicaid): MassHealth, the Massachusetts Medicaid program, maintains its own drug list. GLP-1 coverage under MassHealth has historically required prior authorization and documentation of metformin failure. Members enrolled in BCBS MA's MassHealth managed care products should verify Trulicity's status through the MassHealth Drug List published by the Massachusetts Executive Office of Health and Human Services.

Prior Authorization Criteria for Trulicity at BCBS MA

Prior authorization (PA) is nearly universal for Trulicity at BCBS MA. Typical PA criteria include:

• Diagnosis of type 2 diabetes confirmed by HbA1c ≥7.0%
• Trial and inadequate response or intolerance to metformin (usually 90 days minimum)
• Prescriber attestation that the patient is not using Trulicity for weight loss alone
• Documentation of any prior GLP-1 therapy tried, if applicable
• For the cardiovascular indication: documentation of established ASCVD or high-risk features consistent with the REWIND trial population [3]

The American Diabetes Association Standards of Medical Care in Diabetes, 2024 [5] recommends GLP-1 receptor agonists as preferred agents after metformin for patients with type 2 diabetes and established cardiovascular disease, heart failure, or chronic kidney disease, language that directly supports a PA submission narrative.

How Much Does Trulicity Cost With BCBS MA Coverage?

The list price for Trulicity is approximately $935 per month for the four-pen, once-weekly kit. With BCBS MA coverage at Tier 3, the cost to a member varies widely. Members in a plan with a flat co-pay structure may pay $75, $150 monthly. Members in a coinsurance-based plan paying 25 to 30% of the negotiated rate may pay $200, $300 monthly. Members in high-deductible plans who have not yet met their deductible pay the full negotiated rate, which can still exceed $700 per month before the deductible is satisfied.

Eli Lilly's Savings Program

Eli Lilly offers a co-pay savings card for commercially insured patients. Eligible patients may pay as little as $35 per month per prescription through the Lilly Insulin Value Program or the Trulicity savings card. This card cannot be used with Medicare, Medicaid, or any federal health care program. Patients on BCBS MA commercial plans are generally eligible. Lilly's patient assistance program, Lilly Cares, provides free medication to uninsured or underinsured patients who meet income criteria.

The Role of the Deductible

High-deductible health plans (HDHPs) paired with Health Savings Accounts (HSAs) are common among BCBS MA employer groups. Under an HDHP, the member pays the full negotiated price for Trulicity until the deductible (often $1,500, $3,000 for individuals) is met. The IRS defines HDHP minimum deductibles annually, and the structure means early-year Trulicity fills can be expensive even for members who will eventually have solid coverage.

How to Confirm Your Specific BCBS MA Coverage for Trulicity

Coverage confirmation requires checking the right source. Formularies update annually, and mid-year formulary changes can affect tier placement. Use these steps:

Step 1: Check the BCBS MA Online Formulary Tool

Log in to your BCBS MA member account at bluecrossma.org and manage to the drug formulary or "Find a Drug" tool. Enter "dulaglutide" or "Trulicity." The tool displays the current tier, any PA requirements, and the estimated cost-sharing.

Step 2: Call Member Services

The phone number on the back of your member ID card connects to BCBS MA's pharmacy benefit team. Ask specifically: (1) Is Trulicity on my formulary? (2) What tier? (3) Is prior authorization required? (4) What are the PA criteria? (5) What is my estimated co-pay after my current deductible balance?

Step 3: Ask Your Prescriber to Submit a PA

If PA is required, your endocrinologist or primary care physician submits the request with your diabetes diagnosis, HbA1c history, prior medication trials, and any cardiovascular comorbidities. The ADA 2024 Standards of Care [5] provide clinical language that supports the medical necessity argument.

Step 4: Appeal a Denial

If BCBS MA denies the PA, you have the right to appeal. Massachusetts insurance law requires insurers to respond to expedited appeals within 72 hours and standard appeals within 30 days. The denial letter must specify the clinical criteria not met, which tells your prescriber exactly what additional documentation to supply.

Alternatives to Trulicity That BCBS MA May Cover More Favorably

If Trulicity is denied or the cost-sharing is prohibitive, other GLP-1 receptor agonists and related agents may sit at a lower tier on your specific BCBS MA plan.

Ozempic (Semaglutide 0.5 mg, 1 mg, 2 mg)

Ozempic is a once-weekly injectable GLP-1 agonist. The SUSTAIN-6 trial (N=3,297, 104 weeks) showed semaglutide reduced the rate of nonfatal MI, nonfatal stroke, or cardiovascular death by 26% vs. Placebo (HR 0.74; 95% CI 0.58 to 0.95; P<0.001 for noninferiority). SUSTAIN-6, NEJM [6] Some BCBS MA formularies place Ozempic at Tier 3 with PA requirements similar to Trulicity. Because both are GLP-1 agonists with cardiovascular outcome trial data, the choice between them often comes down to formulary tier and prescriber preference rather than clinical superiority.

Victoza (Liraglutide 1.2 mg, 1.8 mg)

Victoza is a once-daily injectable GLP-1 agonist. The LEADER trial (N=9,340, median 3.8 years) showed liraglutide reduced major adverse cardiovascular events by 13% vs. Placebo (HR 0.87; 95% CI 0.78 to 0.97; P<0.001 for noninferiority; P=0.01 for superiority). LEADER trial, NEJM [7] Victoza has been on the market since 2010 and appears on more formularies at lower tiers in some BCBS MA plan designs. Daily dosing is a drawback for some patients.

Rybelsus (Oral Semaglutide 3 mg, 7 mg, 14 mg)

Rybelsus is the only oral GLP-1 receptor agonist approved in the United States. The PIONEER 6 trial (N=3,183) demonstrated noninferiority to placebo for cardiovascular safety (HR 0.79; 95% CI 0.57 to 1.11). PIONEER 6, NEJM [8] Some patients who prefer oral medications over injections may find Rybelsus covered at a comparable or lower tier on BCBS MA plans. The clinical effect on HbA1c is generally similar to injectable GLP-1 agents at equivalent doses, though absorption requires specific administration conditions (fasting, small sip of water, 30-minute wait before eating).

SGLT-2 Inhibitors as Complementary or Alternative Agents

When GLP-1 coverage is difficult, the ADA 2024 Standards of Care [5] support SGLT-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) as alternatives with proven cardiovascular and renal benefits. The EMPA-REG OUTCOME trial (N=7,020) showed empagliflozin reduced cardiovascular death by 38% vs. Placebo (HR 0.62; 95% CI 0.49 to 0.77; P<0.001). EMPA-REG, NEJM [9] SGLT-2 inhibitors are often at lower formulary tiers because generic empagliflozin and dapagliflozin have entered or are nearing the market.

The Clinical Evidence Behind Trulicity: Why Physicians Prescribe It

Understanding why a physician chooses Trulicity helps frame the medical necessity argument for prior authorization.

Glycemic Efficacy

The AWARD-5 trial (N=1,098, 104 weeks) compared dulaglutide 1.5 mg with sitagliptin 100 mg in patients with type 2 diabetes inadequately controlled on metformin. Dulaglutide produced a mean HbA1c reduction of 0.99% vs. 0.46% for sitagliptin at 104 weeks (P<0.001). AWARD-5, Diabetes Care [10] That degree of glycemic separation, combined with once-weekly dosing and no requirement for dose titration beyond the first four weeks, explains broad prescriber adoption.

Body Weight Effects

Dulaglutide 1.5 mg produced a mean weight loss of approximately 3 kg over 52 weeks in the AWARD program, which is clinically meaningful for patients with type 2 diabetes and obesity though modest compared to semaglutide 2.4 mg. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg for obesity produced 14.9% mean body weight loss at 68 weeks vs. 2.4% for placebo. STEP-1, NEJM [11] Trulicity is not FDA-approved for weight management; prescribers selecting it for weight loss alone would not meet BCBS MA's PA criteria.

Cardiovascular Protection in Established Disease

As noted with the REWIND data [3], dulaglutide's 12% reduction in major adverse cardiovascular events (HR 0.88) over 5.4 years is a clinically actionable finding. The 2023 ACC/AHA Guideline on the Management of Patients with Chronic Coronary Disease [12] includes GLP-1 receptor agonists with proven cardiovascular benefit as a recommended treatment consideration for patients with type 2 diabetes and coronary artery disease, giving prescribers guideline-based language to cite in PA submissions.

Kidney Safety Data

Post-hoc analysis of the REWIND trial found dulaglutide reduced the incidence of new macroalbuminuria by 23% compared to placebo (HR 0.77; 95% CI 0.68 to 0.87; P<0.0001). PubMed PMID 33053940 [13] For patients with early diabetic nephropathy, this renal protection data may supplement the PA narrative, particularly when BCBS MA's medical policy addresses renal comorbidities.

What Happens When BCBS MA Denies Trulicity Coverage?

A PA denial is not the end of the road. The appeals process, step therapy requirements, and patient assistance programs all provide paths forward.

Step Therapy and "Fail-First" Policies

BCBS MA, like most commercial insurers, may require step therapy: the patient must try a less expensive agent first and document that it failed before the plan covers Trulicity. Massachusetts state law (M.G.L. C. 176O) governs step therapy requirements for commercial plans and allows overrides when the required medication is clinically contraindicated or the patient has already tried and failed it. Your physician's office can request a step therapy override with supporting documentation.

Formulary Exception Requests

A formulary exception asks BCBS MA to cover Trulicity at a lower tier or without PA if a covered alternative is medically inappropriate. The CMS guidance on formulary exceptions [14] outlines the process for Medicare plans; commercial plans follow similar logic under BCBS MA's internal policy.

External Appeal Rights Under Massachusetts Law

If BCBS MA upholds the denial after internal appeal, Massachusetts law entitles members to an independent external review through the Division of Insurance. The external reviewer, a board-certified physician unaffiliated with BCBS MA, issues a binding decision. This right applies to any denial based on medical necessity.

Patient Assistance Programs When Coverage Fails Entirely

Eli Lilly's patient assistance program provides Trulicity at no cost to patients who meet income eligibility criteria and lack adequate insurance coverage. Income thresholds and documentation requirements are available directly from Lilly. The National Alliance on Mental Illness's prescription assistance resource and NeedyMeds database [15] can direct patients to the appropriate programs.

Monitoring Requirements Once Trulicity Is Approved and Started

Coverage approval is one milestone; clinical management is another. Once BCBS MA approves Trulicity and the patient starts the medication, ongoing monitoring affects both clinical outcomes and continued PA renewals.

HbA1c Monitoring Schedule

The ADA 2024 Standards of Care [5] recommend HbA1c testing every three months until the target is reached, then every six months in stable patients. BCBS MA PA renewals often require proof of clinical response, typically an HbA1c reduction of at least 0.5% or documented attainment of the individualized glycemic target, within the first 6 to 12 months of therapy.

Renal Function and Dose Considerations

Dulaglutide does not require dose adjustment for renal impairment, a clinical advantage over some oral diabetes agents. The FDA label [1] notes that GFR below 15 mL/min/1.73m² has not been adequately studied, so use in advanced CKD requires clinical judgment. Periodic monitoring of serum creatinine and eGFR is standard of care per KDIGO 2022 CKD guidelines [16].

Gastrointestinal Side Effects and Dose Titration

Nausea, vomiting, and diarrhea are the most common reasons patients discontinue Trulicity. Starting at 0.75 mg once weekly for four weeks before escalating to 1.5 mg reduces GI side effect burden. For patients requiring further glycemic control, doses of 3 mg and 4.5 mg are available. The AWARD-11 trial (N=1,842) showed dulaglutide 4.5 mg reduced HbA1c by 1.87% vs. 1.56% for the 1.5 mg dose (P<0.0001). AWARD-11, The Lancet Diabetes and Endocrinology [17] If a patient discontinues due to GI intolerance, the PA denial on re-initiation may require documentation of the prior intolerance and a clinical rationale for retry or alternative GLP-1 selection.